Hyperosmolar hyperglycemic syndrome induced by diazoxide and furosemide in a 5-year-old girl.

Hyperosmolar hyperglycemic syndrome congenital hyperinsulinemia diazoxide furosemide

Journal

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
ISSN: 0918-5739
Titre abrégé: Clin Pediatr Endocrinol
Pays: Japan
ID NLM: 9433330

Informations de publication

Date de publication:
2021
Historique:
received: 25 01 2021
accepted: 28 03 2021
entrez: 21 7 2021
pubmed: 22 7 2021
medline: 22 7 2021
Statut: ppublish

Résumé

Hyperglycemia and hyperosmolar hyperglycemic syndrome (HHS) are the rare adverse effects of diazoxide. Furosemide has been reported to worsen glucose tolerance and cause HHS. A 5-yr-old girl presented to the emergency department with complaints of tachycardia, polyuria, and lethargy for 1 wk prior to hospitalization. She was treated with two diuretics for aortic valve reflux disease and diazoxide for congenital hyperinsulinemia. She was diagnosed with HHS based on her serum glucose level of 529 mg/dL and serum osmotic pressure of 357 mOsm/kg. There were no findings suggestive of new-onset diabetes mellitus. She had fever on admission and, was diagnosed with a urinary tract infection. The blood diazoxide level at the time of hospitalization was 25 µg/dL. Diazoxide use, even in patients with low diazoxide levels, may cause hyperglycemia. Patients on diuretics and diazoxide must be carefully monitored, considering the risk of developing HHS.

Identifiants

pubmed: 34285456
doi: 10.1297/cpe.30.139
pii: 2021-0003
pmc: PMC8267552
doi:

Types de publication

Case Reports

Langues

eng

Pagination

139-142

Informations de copyright

2021©The Japanese Society for Pediatric Endocrinology.

Références

Pediatr Diabetes. 2018 Oct;19 Suppl 27:155-177
pubmed: 29900641
Proc (Bayl Univ Med Cent). 2019 Aug 13;32(4):627-628
pubmed: 31656445
BMJ. 2019 May 29;365:l1114
pubmed: 31142480
J Pediatr. 1971 Mar;78(3):523-5
pubmed: 5544160
Ulster Med J. 1977;46(2):123-6
pubmed: 929767
J Clin Res Pediatr Endocrinol. 2017 Dec 30;9(Suppl 2):69-87
pubmed: 29280746
Clin Pediatr Endocrinol. 2017;26(3):127-152
pubmed: 28804205
J Pediatr Endocrinol Metab. 2018 Aug 28;31(8):943-945
pubmed: 29958183
Horm Res Paediatr. 2017;88(5):316-323
pubmed: 28715810
Br J Pharmacol. 1973 Jan;47(1):124-32
pubmed: 4717012

Auteurs

Haruka Nakazawa (H)

The Department of Pediatrics, Matsudo City General Hospital Centre, Children's Medical Centre, Matsudo, Japan.

Yuki Naruse (Y)

The Department of Pediatrics, Matsudo City General Hospital Centre, Children's Medical Centre, Matsudo, Japan.

Masato Mori (M)

The Department of Pediatrics, Matsudo City General Hospital Centre, Children's Medical Centre, Matsudo, Japan.

Ryugo Hiramoto (R)

The Department of Pediatrics, Matsudo City General Hospital Centre, Children's Medical Centre, Matsudo, Japan.

Classifications MeSH